NASDAQ: ADRXAdarx Pharmaceuticals Inc Stock
$14.91+1.61 (+12.11%)
Updated Nov 12, 2026
ADRX Price
$14.91
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$12.50
52 Week High
$23.21
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.39
Operating Cash Flow
N/A
Beta
1.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADRX Overview
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADRX
Ranked#104 of 451
Ranked#104 of 451
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.65 | A | |
| $951.19 | A | |
| $415.96 | A |
Be the first to know about important ADRX news, forecast changes, insider trades & much more!
ADRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADRX's short-term assets ($441.54M) exceed its short-term liabilities ($34.01M)
Short-term Liabilities Financials
ADRX's short-term assets ($441.54M) exceed its long-term liabilities ($315.75M)
Long-term Liabilities Financials
ADRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more ADRX due diligence checks available for Premium users.
Valuation
ADRX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$456.3M
Liabilities
$349.8M
Debt to equity
-1.39
ADRX's short-term assets ($441.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADRX's short-term assets ($441.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Adarx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.